Short answer
Insulet Corporation (PODD) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Michael R. Minogue reappointed as Class I director effective November 20, 2026, term through 2029 annual meeting.
Insulet Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Michael R. Minogue reappointed as Class I director effective November 20, 2026, term through 2029 annual meeting
- Return restores prior healthcare leadership and medtech expertise following September 2026 resignation
- Former Abiomed chairman and CEO through its December 2022 sale, adding medical-device operating experience
- Approximately $121,700 restricted stock unit grant, representing prorated portion of $260,000 annual equity award
- Additional cash compensation under Insulet’s non-employee director program
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insulet Corporation 8-K filings
Get the next PODD 8-K as it lands
Follow PODD for push alerts, or ask the research agent what this filing means.